FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043800892> ?p ?o ?g. }

• W2043800892 endingPage "S209" @default.
• W2043800892 startingPage "S208" @default.
• W2043800892 abstract "High dose chemotherapy with autologous stem cell transplant (ASCT) improves survival in patients with aggressive non-Hodgkin's lymphoma (NHL), but relapse occurs in 40-50% of patients. Rituximab exerts its anti-tumor effect through complement and antibody-dependent cell cytotoxicity (ADCC). Sargramostim is involved in the activation and differentiation of macrophages and dendritic cells and increases monocyte-mediated ADCC. The addition of sargramostim to rituximab may potentiate the anti-tumor effect of rituximab by enhancing recruitment and activation of effector cells that mediate ADCC. We evaluated the safety and efficacy of rituximab and sargramostim given as “adjuvant immunotherapy” to patients following ASCT for aggressive NHL. 8 patients (5 male, 3 female; median age 53, range 34-69) with CD20+ diffuse large B cell (6) or mantle cell (2) NHL relapsed, primary refractory or in first complete remission (intermediate-high or high risk IPI) underwent stem cell mobilization using rituximab and cyclophosphamide followed by high dose chemotherapy with rituximab, carmustine, etoposide, cytarabine and melphalan. Adjuvant immunotherapy consisted of rituximab 375 mg/M2 IV weekly and sargramostim 250 ug s.c. TIW during weeks 5 to 8 and 24 to 27 post transplant. Seven patients had successful mobilization (mean CD34/kg collected 12.5E6 and infused 9E6) and underwent transplant. Median time to neutrophil and platelet engraftment was 9 and 10 days respectively. Six patients are alive with no evidence of disease from 3 to 18 months post transplant. One patient relapsed at 11 months. 4/4 patients receiving at least once cycle of adjuvant immunotherapy developed grade 1 to 4 neutropenia from 3 to 34 weeks post adjuvant rituximab. Neutrophil counts recovered following treatment with G-CSF, but recurred in all 4 patients without additional exposure to rituximab. One patient who had engrafted platelets developed grade 2 thrombocytopenia on day 33 post transplant. Platelets spontaneously recovered. Delayed-onset neutropenia is a known complication of rituximab. The incidence may be higher when rituximab is used following ASCT. It is not clear if the timing of rituximab administration post transplant or the concomitant use of sargramostim contributed to the high incidence of delayed neutropenia in this study. Larger studies and longer followup will be needed to determine if adjuvant immunotherapy decreases relapse." @default.
• W2043800892 created "2016-06-24" @default.
• W2043800892 creator A5007648507 @default.
• W2043800892 creator A5025051482 @default.
• W2043800892 creator A5031370568 @default.
• W2043800892 creator A5062516204 @default.
• W2043800892 creator A5077111763 @default.
• W2043800892 creator A5079692646 @default.
• W2043800892 date "2010-02-01" @default.
• W2043800892 modified "2023-09-25" @default.
• W2043800892 title "Rituximab And Sargramostim Immunotherapy Following Autologous Stem Cell Transplant For Aggressive Non-Hodgkin's Lymphoma" @default.
• W2043800892 doi "https://doi.org/10.1016/j.bbmt.2009.12.167" @default.
• W2043800892 hasPublicationYear "2010" @default.
• W2043800892 type Work @default.
• W2043800892 sameAs 2043800892 @default.
• W2043800892 citedByCount "0" @default.
• W2043800892 crossrefType "journal-article" @default.
• W2043800892 hasAuthorship W2043800892A5007648507 @default.
• W2043800892 hasAuthorship W2043800892A5025051482 @default.
• W2043800892 hasAuthorship W2043800892A5031370568 @default.
• W2043800892 hasAuthorship W2043800892A5062516204 @default.
• W2043800892 hasAuthorship W2043800892A5077111763 @default.
• W2043800892 hasAuthorship W2043800892A5079692646 @default.
• W2043800892 hasBestOaLocation W20438008921 @default.
• W2043800892 hasConcept C126322002 @default.
• W2043800892 hasConcept C143998085 @default.
• W2043800892 hasConcept C203014093 @default.
• W2043800892 hasConcept C2776694085 @default.
• W2043800892 hasConcept C2776755627 @default.
• W2043800892 hasConcept C2777525834 @default.
• W2043800892 hasConcept C2779050716 @default.
• W2043800892 hasConcept C2779338263 @default.
• W2043800892 hasConcept C2780147359 @default.
• W2043800892 hasConcept C2780653079 @default.
• W2043800892 hasConcept C2911091166 @default.
• W2043800892 hasConcept C71924100 @default.
• W2043800892 hasConcept C90924648 @default.
• W2043800892 hasConceptScore W2043800892C126322002 @default.
• W2043800892 hasConceptScore W2043800892C143998085 @default.
• W2043800892 hasConceptScore W2043800892C203014093 @default.
• W2043800892 hasConceptScore W2043800892C2776694085 @default.
• W2043800892 hasConceptScore W2043800892C2776755627 @default.
• W2043800892 hasConceptScore W2043800892C2777525834 @default.
• W2043800892 hasConceptScore W2043800892C2779050716 @default.
• W2043800892 hasConceptScore W2043800892C2779338263 @default.
• W2043800892 hasConceptScore W2043800892C2780147359 @default.
• W2043800892 hasConceptScore W2043800892C2780653079 @default.
• W2043800892 hasConceptScore W2043800892C2911091166 @default.
• W2043800892 hasConceptScore W2043800892C71924100 @default.
• W2043800892 hasConceptScore W2043800892C90924648 @default.
• W2043800892 hasIssue "2" @default.
• W2043800892 hasLocation W20438008921 @default.
• W2043800892 hasOpenAccess W2043800892 @default.
• W2043800892 hasPrimaryLocation W20438008921 @default.
• W2043800892 hasRelatedWork W2005973506 @default.
• W2043800892 hasRelatedWork W2079542323 @default.
• W2043800892 hasRelatedWork W2168627855 @default.
• W2043800892 hasRelatedWork W2175821410 @default.
• W2043800892 hasRelatedWork W2261580366 @default.
• W2043800892 hasRelatedWork W2412433018 @default.
• W2043800892 hasRelatedWork W2582565029 @default.
• W2043800892 hasRelatedWork W2745982028 @default.
• W2043800892 hasRelatedWork W2995371026 @default.
• W2043800892 hasRelatedWork W4233157026 @default.
• W2043800892 hasVolume "16" @default.
• W2043800892 isParatext "false" @default.
• W2043800892 isRetracted "false" @default.
• W2043800892 magId "2043800892" @default.
• W2043800892 workType "article" @default.